298. Hereditary pancreatitis Clinical trials / Disease details

Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02869893 (ClinicalTrials.gov)	August 10, 2016	5/6/2016	MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics	Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics	Healthy Volunteers	Drug: Secretin	Children's Hospital Medical Center, Cincinnati	ChiRhoClin, Inc.;The National Pancreas Foundation	Completed	6 Years	15 Years	All	57	N/A	United States
2	NCT02458118 (ClinicalTrials.gov)	June 2012	27/5/2015	Pancreatic Perfusion Using Secretin and MRI	Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis	Chronic Pancreatitis	Drug: Secretin	University of Nottingham	NULL	Recruiting	18 Years	80 Years	Both	15	Phase 1/Phase 2	United Kingdom
3	NCT01265875 (ClinicalTrials.gov)	December 2010	22/12/2010	Secretin Infusion for Pain Due to Chronic Pancreatitis	Secretin Infusion for Pain Due to Chronic Pancreatitis	Chronic Pancreatitis	Drug: Human Secretin	ChiRhoClin, Inc.	Dartmouth-Hitchcock Medical Center	Completed	18 Years	70 Years	All	12	Phase 1/Phase 2	United States
4	NCT01452217 (ClinicalTrials.gov)	September 2010	10/10/2011	Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers	The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers	Chronic Pancreatitis	Drug: Secretin	University of Nottingham	NULL	Completed	18 Years	75 Years	Male	12	Phase 1	United Kingdom
5	NCT00621283 (ClinicalTrials.gov)	February 2008	22/1/2008	Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population	RG1068 (Synthetic Human Secretin) Enhanced MRCP for Morphological Evaluation of the Pancreatic Duct in the Pediatric Population	Acute Recurrent Pancreatitis;Chronic Pancreatitis	Drug: RG1068 (Synthetic Human Secretin)	Massachusetts General Hospital	NULL	Terminated	2 Years	18 Years	Both	0	Phase 1	United States
6	NCT00620919 (ClinicalTrials.gov)	February 2008	22/1/2008	Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis	RG1068 (Synthetic Human Secretin) Enhanced Multidetector CT Pancreatography: Evaluation of the Pancreatic Duct in Patients With Known or Suspected Chronic Pancreatitis	Chronic Pancreatitis	Drug: RG1068 (Synthetic Human Secretin)	Massachusetts General Hospital	NULL	Terminated	18 Years	90 Years	Both	0	Phase 1	United States